Clinical Neuroscience Research Unit

Connecticut Mental Health Center

34 Park Street

New Haven, CT 06519

Directions

1 of 3

Clinical Neuroscience Research Unit
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519
- Directions
Yale Depression Research Clinic
100 York Street
Ste 2J
New Haven, CT 06511
- 1-203-764-9131
- Directions
Interventional Psychiatary
Yale New Haven Hospital - West Pavilion
1 Park Street
New Haven, CT 06504
- 1-844-228-5078
- Directions

View Academic Profile

Click here to view more about this specialist's research and educational efforts on https://medicine.yale.edu

Click here to view more about this specialist's research and educational efforts onhttps://medicine.yale.edu

Gerard Sanacora, PhD, MD

Psychiatry

Telehealth is available

Learn more about telehealth

Patient type treated

Child, Adult

Accepting new patients

Referral required

Not Applicable

Board Certified in

Psychiatry

Insurance accepted

View Academic Profile

Click here to view more about this specialist's research and educational efforts on https://medicine.yale.edu

Click here to view more about this specialist's research and educational efforts onhttps://medicine.yale.edu

Biography

Dr. Sanacora is a Professor of Psychiatry at Yale University and the Director of the Yale Depression Research Program. Dr. Sanacora’s work has focused largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders and using this information to inform the development of novel treatment strategies. His preclinical research laboratory explores the effects of stress and pharmaceutical agents on cellular biology, neurophysiology and behavior. His clinical laboratory employs novel imaging methodologies to investigate the pathophysiology of mood and other neuropsychiatric disorders. In addition, he has served as principal investigator on several large clinical trials investigating the efficacy and safety of newly developed therapeutic agents for the treatment of mood disorders. Dr. Sanacora received the Anna-Monkia Stiftung international award for the investigation of the biological substrate and functional disturbances of depression in 2009, the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the American College of Neuropsychopharmacology (ACNP) in 2011, and is a Fellow of the ACNP.

Titles

George D. and Esther S. Gross Professor of Psychiatry
Director, Yale Depression Research Program
Co-Director, Yale New Haven Hospital Interventional Psychiatry Service

Education & Training

Fellow
Yale University School of Medicine (1999)
Resident
Yale University School of Medicine (1998)
MD
SUNY at Stonybrook (1994)
PhD
SUNY at Stonybrook (1992)
Post Doctoral
SUNY Stony Brook (1992)

Additional Information

Honors & Recognitions

Publications

Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models
Bansal Y, Fee C, Misquitta K, Codeluppi S, Sibille E, Berman R, Coric V, Sanacora G, Banasr M. Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models Complex Psychiatry 2023 DOI: 10.1159/000529534.
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine
Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine The Journal Of Clinical Psychiatry 2022, 84 DOI: 10.4088/jcp.22m14991.
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. The Journal Of Clinical Psychiatry 2022, 84 PMID: 36383742, DOI: 10.4088/jcp.22m14491.
Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder Biological Psychiatry 2022 PMID: 36764853, DOI: 10.1016/j.biopsych.2022.10.018.
Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder Biological Psychiatry 2022 DOI: 10.1016/j.biopsych.2022.10.018.
Imaging the Effect of Ketamine on Synaptic (SV2A) Density
Holmes S, Finnema S, Finnema S, Naganawa M, DellaGioia N, Holden D, Fowles K, Ropchan J, Emory P, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita G, Angarita G, Duman R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. Imaging the Effect of Ketamine on Synaptic (SV2A) Density Biological Psychiatry 2021, 89: s35. DOI: 10.1016/j.biopsych.2021.02.105.
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial FOCUS The Journal Of Lifelong Learning In Psychiatry 2021, 20: 241-251. DOI: 10.1176/appi.focus.22020004.
142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations
Holmes S, Scheinost D, Finnema S, Finnema S, Naganawa M, Davis M, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Angarita G, Pietrzak R, Duman R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. 142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations Biological Psychiatry 2019, 85: s59. DOI: 10.1016/j.biopsych.2019.03.156.
S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis
Webler R, Wilkinson S, Kirwin D, Bloch M, Kitay B, Sanacora G. S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis Biological Psychiatry 2019, 85: s346. DOI: 10.1016/j.biopsych.2019.03.879.
116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients
Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Weiner R, Calabrese J, Sanacora G, Keefe R, Song A, Goodman W, Szabo S, Whitten A, Gao K, Potter W. 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients Biological Psychiatry 2019, 85: s48-s49. DOI: 10.1016/j.biopsych.2019.03.130.
POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION American Journal Of Geriatric Psychiatry 2019, 27: s140-s141. DOI: 10.1016/j.jagp.2019.01.094.
EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION American Journal Of Geriatric Psychiatry 2019, 27: s139-s140. DOI: 10.1016/j.jagp.2019.01.093.
Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.
Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study
Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study European Neuropsychopharmacology 2019, 29: s44-s45. DOI: 10.1016/j.euroneuro.2018.11.1016.
Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression European Neuropsychopharmacology 2019, 29: s355-s356. DOI: 10.1016/j.euroneuro.2018.11.548.
Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2)
Wajs E, Aluisio L, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2) French Journal Of Psychiatry 2018, 1: s176. DOI: 10.1016/s2590-2415(19)30445-3.
F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET
Holmes S, Finnema S, Finnema S, Davis M, Davis M, DellaGioia N, Naganawa M, Nabulsi N, Matuskey D, Pietrzak R, Duman R, Duman R, Sanacora G, Carson R, Esterlis I. F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET Biological Psychiatry 2018, 83: s296. DOI: 10.1016/j.biopsych.2018.02.763.
S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital
Wilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital Biological Psychiatry 2018, 83: s388. DOI: 10.1016/j.biopsych.2018.02.997.
S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression Biological Psychiatry 2018, 83: s391. DOI: 10.1016/j.biopsych.2018.02.1005.
662 Ketamine and Rapastinel Effects on Glutamate Cycling
Sanacora G, Chowdhury G, Rothman D, Behar K. 662 Ketamine and Rapastinel Effects on Glutamate Cycling Biological Psychiatry 2017, 81: s268. DOI: 10.1016/j.biopsych.2017.02.1071.
1002 Ketamine as a Treatment for Adolescent Major Depressive Disorder
Dwyer J, Sanacora G, Bloch M. 1002 Ketamine as a Treatment for Adolescent Major Depressive Disorder Biological Psychiatry 2017, 81: s405. DOI: 10.1016/j.biopsych.2017.02.729.
201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression
Sanacora G, Wilkinson S, Van Schalkwyk G. 201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression Biological Psychiatry 2017, 81: s83. DOI: 10.1016/j.biopsych.2017.02.214.
Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy
Ostroff R, Wilkinson S, Sanacora G. Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy Brain Stimulation 2017, 10: 524. DOI: 10.1016/j.brs.2017.01.529.
Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
Hermes G, Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies 2016, 73-98. DOI: 10.1007/978-3-319-42925-0_6.
Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
Sanacora G, Heimer H, Hartman D, Mathew S, Frye M, Nemeroff C, Robinson Beale R. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders Neuropsychopharmacology 2016, 42: 1179-1181. PMID: 27640324, PMCID: PMC5437876, DOI: 10.1038/npp.2016.193.
Speaker 4: John Krystal, USA
Krystal J, Sanacora G, Abdallah C, Duman R. Speaker 4: John Krystal, USA The International Journal Of Neuropsychopharmacology 2016, 19: 19-19. PMCID: PMC5616528, DOI: 10.1093/ijnp/pyw042.052.
P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study
Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, Van Nueten L. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study European Neuropsychopharmacology 2014, 24: s387-s388. DOI: 10.1016/s0924-977x(14)70618-2.
Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies
Kiselycznyk C, Sanacora G. Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies 2014, 313-341. DOI: 10.1007/978-1-4939-1056-4_17.
The Revolution in Rapid-Acting Antidepressants
Sanacora G, Duman R. The Revolution in Rapid-Acting Antidepressants Biological Psychiatry 2013, 73: 1123-1124. DOI: 10.1016/j.biopsych.2013.04.020.
Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting Journal Of Ect 2012, 28: 157-161. PMID: 22847373, PMCID: PMC3426617, DOI: 10.1097/yct.0b013e31824f8296.
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients Biological Psychiatry 2012, 72: e27-e28. PMID: 22771240, PMCID: PMC3786174, DOI: 10.1016/j.biopsych.2012.05.031.
Cortical GABA Levels in Primary Insomnia
Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G. Cortical GABA Levels in Primary Insomnia Sleep 2012, 35: 807-814. PMID: 22654200, PMCID: PMC3353043, DOI: 10.5665/sleep.1880.
1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism
Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission Nature Reviews Neuroscience 2011, 13: 22-37. PMID: 22127301, PMCID: PMC3645314, DOI: 10.1038/nrn3138.
P03-437 - A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department
Larkin G, Beautrais A, Turelli R, Sanacora G, Powsner S, Lippmann M, Krystal J. P03-437 - A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department European Psychiatry 2011, 26: 1607. DOI: 10.1016/s0924-9338(11)73311-9.
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.
157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department
Larkin G, Beautrais A, Powsner S, Sanacora G, Krystal J, Turelli R, Lippmann M. 157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department Annals Of Emergency Medicine 2010, 56: s53. DOI: 10.1016/j.annemergmed.2010.06.204.
S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole
Sanacora G, Banasr M, Chowdhury G, Lepak A, Behar K. S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole European Neuropsychopharmacology 2010, 20: s208. DOI: 10.1016/s0924-977x(10)70241-8.
P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial
Saricicek A, Maloney K, Lorberg B, Muralidharan A, Ruf B, Blumberg H, Hu J, Pittman B, Sanacora G, Bhagwagar Z. P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial European Neuropsychopharmacology 2009, 19: s465. DOI: 10.1016/s0924-977x(09)70728-x.
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.
Neurobiology and Treatment of Depression
Neumeister A, Charney D, Sanacora G, Krystal J. Neurobiology and Treatment of Depression 2007 DOI: 10.1002/9780470101001.hcn018.
Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders
Sanacora G. Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders 2002, 739-749. DOI: 10.1002/0470854871.chxviii3.
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.
ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment
Chen A, Shin K, Duman R, Sanacora G. ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment Journal Of Ect 2001, 17: 27-32. PMID: 11281511, DOI: 10.1097/00124509-200103000-00006.
268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects
Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects Biological Psychiatry 2000, 47: s81. DOI: 10.1016/s0006-3223(00)00532-1.
304. Cortical GABA reduced in unipolar but not bipolar depression
Mason G, Sanacora G, Anand A, Anand A, Epperson C, Goddard A, Goddard A, Rothman D, Charney D, Charney D, Krystal J. 304. Cortical GABA reduced in unipolar but not bipolar depression Biological Psychiatry 2000, 47: s92. DOI: 10.1016/s0006-3223(00)00568-0.
305. Reduced cortical GABA in depression is not due to decreased gray matter
Sanacora G, Mason G, Rothman D, Epperson C, Goddard A, Goddard A, Krystal J. 305. Reduced cortical GABA in depression is not due to decreased gray matter Biological Psychiatry 2000, 47: s92. DOI: 10.1016/s0006-3223(00)00569-2.
A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression
Berman R, Narasimhan M, Sanacora G, Miano A, Hoffman R, Hu X, Charney D, Boutros N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression Biological Psychiatry 2000, 47: 332-337. PMID: 10686268, DOI: 10.1016/s0006-3223(99)00243-7.
Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies
Sanacora G, Mason G, Krystal J. Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies Critical Reviews In Neurobiology 2000, 14: 23. PMID: 11253954, DOI: 10.1615/critrevneurobiol.v14.i1.20.
Applications of Magnetic Resonance Spectroscopy to Psychiatry
Sanacora G, Rothman D, Krystal J. Applications of Magnetic Resonance Spectroscopy to Psychiatry The Neuroscientist 1999, 5: 192-196. DOI: 10.1177/107385849900500316.
1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS
Sanacora G, Mason G, Rothman D, Berman R, Charney D, Ciarcia J, Krystal J. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS Journal Of Ect 1999, 15: 102. DOI: 10.1097/00124509-199903000-00009.
8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting
Sanacora G, Chen A, Shin K, Duman R. 8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting Journal Of Ect 1999, 15: 109. DOI: 10.1097/00124509-199903000-00028.
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography
Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.
24. Quantification of cortical GABA levels in neuropsychiatric patients
Sanacora G, Goddard A, Gil R, D'Souza D, Abi-Saab W, Petroff O, Mattson R, Mason G, Behar K, Ciarcia J, Berman R, Charney D, Rothman D, Krystal J. 24. Quantification of cortical GABA levels in neuropsychiatric patients Biological Psychiatry 1998, 43: s8. DOI: 10.1016/s0006-3223(98)90472-3.
322. Transcranial magnetic stimulation in treatment-refractory depression
Berman R, Boutros N, Narasimhan M, Sanacora G, Charney D. 322. Transcranial magnetic stimulation in treatment-refractory depression Biological Psychiatry 1998, 43: s97. DOI: 10.1016/s0006-3223(98)90770-3.

Patient Care Organizations

View Academic Profile

Click here to view more about this specialist's research and educational efforts on https://medicine.yale.edu

Click here to view more about this specialist's research and educational efforts onhttps://medicine.yale.edu

Biography

Titles

George D. and Esther S. Gross Professor of Psychiatry
Director, Yale Depression Research Program
Co-Director, Yale New Haven Hospital Interventional Psychiatry Service

Education & Training

Fellow
Yale University School of Medicine (1999)
Resident
Yale University School of Medicine (1998)
MD
SUNY at Stonybrook (1994)
PhD
SUNY at Stonybrook (1992)
Post Doctoral
SUNY Stony Brook (1992)

Additional Information

Honors & Recognitions

Publications

Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models
Bansal Y, Fee C, Misquitta K, Codeluppi S, Sibille E, Berman R, Coric V, Sanacora G, Banasr M. Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models Complex Psychiatry 2023 DOI: 10.1159/000529534.
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine
Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine The Journal Of Clinical Psychiatry 2022, 84 DOI: 10.4088/jcp.22m14991.
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. The Journal Of Clinical Psychiatry 2022, 84 PMID: 36383742, DOI: 10.4088/jcp.22m14491.
Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder Biological Psychiatry 2022 PMID: 36764853, DOI: 10.1016/j.biopsych.2022.10.018.
Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder Biological Psychiatry 2022 DOI: 10.1016/j.biopsych.2022.10.018.
Imaging the Effect of Ketamine on Synaptic (SV2A) Density
Holmes S, Finnema S, Finnema S, Naganawa M, DellaGioia N, Holden D, Fowles K, Ropchan J, Emory P, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita G, Angarita G, Duman R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. Imaging the Effect of Ketamine on Synaptic (SV2A) Density Biological Psychiatry 2021, 89: s35. DOI: 10.1016/j.biopsych.2021.02.105.
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial FOCUS The Journal Of Lifelong Learning In Psychiatry 2021, 20: 241-251. DOI: 10.1176/appi.focus.22020004.
142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations
Holmes S, Scheinost D, Finnema S, Finnema S, Naganawa M, Davis M, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Angarita G, Pietrzak R, Duman R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. 142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations Biological Psychiatry 2019, 85: s59. DOI: 10.1016/j.biopsych.2019.03.156.
S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis
Webler R, Wilkinson S, Kirwin D, Bloch M, Kitay B, Sanacora G. S128. Expectancy and Ketamine’s Rapid Antidepressant Effect: A Meta-Analysis Biological Psychiatry 2019, 85: s346. DOI: 10.1016/j.biopsych.2019.03.879.
116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients
Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger J, Lisanby S, Iosifescu D, Murrough J, Weiner R, Calabrese J, Sanacora G, Keefe R, Song A, Goodman W, Szabo S, Whitten A, Gao K, Potter W. 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients Biological Psychiatry 2019, 85: s48-s49. DOI: 10.1016/j.biopsych.2019.03.130.
POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION American Journal Of Geriatric Psychiatry 2019, 27: s140-s141. DOI: 10.1016/j.jagp.2019.01.094.
EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION American Journal Of Geriatric Psychiatry 2019, 27: s139-s140. DOI: 10.1016/j.jagp.2019.01.093.
Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.
Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study
Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study European Neuropsychopharmacology 2019, 29: s44-s45. DOI: 10.1016/j.euroneuro.2018.11.1016.
Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression European Neuropsychopharmacology 2019, 29: s355-s356. DOI: 10.1016/j.euroneuro.2018.11.548.
Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2)
Wajs E, Aluisio L, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Drevets W, Singh J. Etude de phase 3 en ouvert évaluant l’efficacité et la sécurité d’emploi à long terme d’Eskétamine intranasal (ESK IN) associé à un antidépresseur oral chez des patients atteints de dépression résistante (SUSTAIN-2) French Journal Of Psychiatry 2018, 1: s176. DOI: 10.1016/s2590-2415(19)30445-3.
F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET
Holmes S, Finnema S, Finnema S, Davis M, Davis M, DellaGioia N, Naganawa M, Nabulsi N, Matuskey D, Pietrzak R, Duman R, Duman R, Sanacora G, Carson R, Esterlis I. F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET Biological Psychiatry 2018, 83: s296. DOI: 10.1016/j.biopsych.2018.02.763.
S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital
Wilkinson S, Webler R, Katz R, Toprak M, Ostroff R, Sanacora G. S106. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital Biological Psychiatry 2018, 83: s388. DOI: 10.1016/j.biopsych.2018.02.997.
S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression
Ochs-Ross R, Daly E, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets W, Sanacora G, Adler C, McShane R, Gaillard R, Singh J. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression Biological Psychiatry 2018, 83: s391. DOI: 10.1016/j.biopsych.2018.02.1005.
662 Ketamine and Rapastinel Effects on Glutamate Cycling
Sanacora G, Chowdhury G, Rothman D, Behar K. 662 Ketamine and Rapastinel Effects on Glutamate Cycling Biological Psychiatry 2017, 81: s268. DOI: 10.1016/j.biopsych.2017.02.1071.
1002 Ketamine as a Treatment for Adolescent Major Depressive Disorder
Dwyer J, Sanacora G, Bloch M. 1002 Ketamine as a Treatment for Adolescent Major Depressive Disorder Biological Psychiatry 2017, 81: s405. DOI: 10.1016/j.biopsych.2017.02.729.
201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression
Sanacora G, Wilkinson S, Van Schalkwyk G. 201 Measuring Dissociative Effects of NMDA Receptor Antagonists in the Treatment of Depression Biological Psychiatry 2017, 81: s83. DOI: 10.1016/j.biopsych.2017.02.214.
Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy
Ostroff R, Wilkinson S, Sanacora G. Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy Brain Stimulation 2017, 10: 524. DOI: 10.1016/j.brs.2017.01.529.
Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
Hermes G, Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies 2016, 73-98. DOI: 10.1007/978-3-319-42925-0_6.
Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
Sanacora G, Heimer H, Hartman D, Mathew S, Frye M, Nemeroff C, Robinson Beale R. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders Neuropsychopharmacology 2016, 42: 1179-1181. PMID: 27640324, PMCID: PMC5437876, DOI: 10.1038/npp.2016.193.
Speaker 4: John Krystal, USA
Krystal J, Sanacora G, Abdallah C, Duman R. Speaker 4: John Krystal, USA The International Journal Of Neuropsychopharmacology 2016, 19: 19-19. PMCID: PMC5616528, DOI: 10.1093/ijnp/pyw042.052.
P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study
Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, Van Nueten L. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study European Neuropsychopharmacology 2014, 24: s387-s388. DOI: 10.1016/s0924-977x(14)70618-2.
Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies
Kiselycznyk C, Sanacora G. Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies 2014, 313-341. DOI: 10.1007/978-1-4939-1056-4_17.
The Revolution in Rapid-Acting Antidepressants
Sanacora G, Duman R. The Revolution in Rapid-Acting Antidepressants Biological Psychiatry 2013, 73: 1123-1124. DOI: 10.1016/j.biopsych.2013.04.020.
Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting Journal Of Ect 2012, 28: 157-161. PMID: 22847373, PMCID: PMC3426617, DOI: 10.1097/yct.0b013e31824f8296.
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients Biological Psychiatry 2012, 72: e27-e28. PMID: 22771240, PMCID: PMC3786174, DOI: 10.1016/j.biopsych.2012.05.031.
Cortical GABA Levels in Primary Insomnia
Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G. Cortical GABA Levels in Primary Insomnia Sleep 2012, 35: 807-814. PMID: 22654200, PMCID: PMC3353043, DOI: 10.5665/sleep.1880.
1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism
Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission Nature Reviews Neuroscience 2011, 13: 22-37. PMID: 22127301, PMCID: PMC3645314, DOI: 10.1038/nrn3138.
P03-437 - A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department
Larkin G, Beautrais A, Turelli R, Sanacora G, Powsner S, Lippmann M, Krystal J. P03-437 - A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department European Psychiatry 2011, 26: 1607. DOI: 10.1016/s0924-9338(11)73311-9.
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.
157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department
Larkin G, Beautrais A, Powsner S, Sanacora G, Krystal J, Turelli R, Lippmann M. 157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department Annals Of Emergency Medicine 2010, 56: s53. DOI: 10.1016/j.annemergmed.2010.06.204.
S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole
Sanacora G, Banasr M, Chowdhury G, Lepak A, Behar K. S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole European Neuropsychopharmacology 2010, 20: s208. DOI: 10.1016/s0924-977x(10)70241-8.
P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial
Saricicek A, Maloney K, Lorberg B, Muralidharan A, Ruf B, Blumberg H, Hu J, Pittman B, Sanacora G, Bhagwagar Z. P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial European Neuropsychopharmacology 2009, 19: s465. DOI: 10.1016/s0924-977x(09)70728-x.
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.
Neurobiology and Treatment of Depression
Neumeister A, Charney D, Sanacora G, Krystal J. Neurobiology and Treatment of Depression 2007 DOI: 10.1002/9780470101001.hcn018.
Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders
Sanacora G. Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders 2002, 739-749. DOI: 10.1002/0470854871.chxviii3.
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.
ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment
Chen A, Shin K, Duman R, Sanacora G. ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment Journal Of Ect 2001, 17: 27-32. PMID: 11281511, DOI: 10.1097/00124509-200103000-00006.
268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects
Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects Biological Psychiatry 2000, 47: s81. DOI: 10.1016/s0006-3223(00)00532-1.
304. Cortical GABA reduced in unipolar but not bipolar depression
Mason G, Sanacora G, Anand A, Anand A, Epperson C, Goddard A, Goddard A, Rothman D, Charney D, Charney D, Krystal J. 304. Cortical GABA reduced in unipolar but not bipolar depression Biological Psychiatry 2000, 47: s92. DOI: 10.1016/s0006-3223(00)00568-0.
305. Reduced cortical GABA in depression is not due to decreased gray matter
Sanacora G, Mason G, Rothman D, Epperson C, Goddard A, Goddard A, Krystal J. 305. Reduced cortical GABA in depression is not due to decreased gray matter Biological Psychiatry 2000, 47: s92. DOI: 10.1016/s0006-3223(00)00569-2.
A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression
Berman R, Narasimhan M, Sanacora G, Miano A, Hoffman R, Hu X, Charney D, Boutros N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression Biological Psychiatry 2000, 47: 332-337. PMID: 10686268, DOI: 10.1016/s0006-3223(99)00243-7.
Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies
Sanacora G, Mason G, Krystal J. Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies Critical Reviews In Neurobiology 2000, 14: 23. PMID: 11253954, DOI: 10.1615/critrevneurobiol.v14.i1.20.
Applications of Magnetic Resonance Spectroscopy to Psychiatry
Sanacora G, Rothman D, Krystal J. Applications of Magnetic Resonance Spectroscopy to Psychiatry The Neuroscientist 1999, 5: 192-196. DOI: 10.1177/107385849900500316.
1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS
Sanacora G, Mason G, Rothman D, Berman R, Charney D, Ciarcia J, Krystal J. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS Journal Of Ect 1999, 15: 102. DOI: 10.1097/00124509-199903000-00009.
8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting
Sanacora G, Chen A, Shin K, Duman R. 8. Ketamine Effects on ECS Induced BDNF Expression and Mossy Fiber Sprouting Journal Of Ect 1999, 15: 109. DOI: 10.1097/00124509-199903000-00028.
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography
Malison R, Price L, Berman R, van Dyck C, Pelton G, Carpenter L, Sanacora G, Owens M, Nemeroff C, Rajeevan N, Baldwin R, Seibyl J, Innis R, Charney D. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography Biological Psychiatry 1998, 44: 1090-1098. PMID: 9836013, DOI: 10.1016/s0006-3223(98)00272-8.
24. Quantification of cortical GABA levels in neuropsychiatric patients
Sanacora G, Goddard A, Gil R, D'Souza D, Abi-Saab W, Petroff O, Mattson R, Mason G, Behar K, Ciarcia J, Berman R, Charney D, Rothman D, Krystal J. 24. Quantification of cortical GABA levels in neuropsychiatric patients Biological Psychiatry 1998, 43: s8. DOI: 10.1016/s0006-3223(98)90472-3.
322. Transcranial magnetic stimulation in treatment-refractory depression
Berman R, Boutros N, Narasimhan M, Sanacora G, Charney D. 322. Transcranial magnetic stimulation in treatment-refractory depression Biological Psychiatry 1998, 43: s97. DOI: 10.1016/s0006-3223(98)90770-3.

Patient Care Organizations

Clinical Neuroscience Research Unit

Connecticut Mental Health Center

34 Park Street

New Haven, CT 06519

Directions

1 of 3

Clinical Neuroscience Research Unit
Connecticut Mental Health Center
34 Park Street
New Haven, CT 06519
- Directions
Yale Depression Research Clinic
100 York Street
Ste 2J
New Haven, CT 06511
- 1-203-764-9131
- Directions
Interventional Psychiatary
Yale New Haven Hospital - West Pavilion
1 Park Street
New Haven, CT 06504
- 1-844-228-5078
- Directions